Write a short note on hepatorenal syndrome.
Definition
Hepatorenal syndrome (HRS) is a form of functional, potentially reversible acute kidney injury occurring in advanced liver disease with portal hypertension and ascites, in which the kidneys are structurally normal — a fact demonstrated by the observation that a kidney from a patient with HRS functions normally when transplanted into a recipient with normal liver function.
It is a diagnosis of exclusion, made only after other causes of renal failure have been ruled out.
PATHOPHYSIOLOGY — a logical chain worth reproducing in an answer
1. Portal hypertension → release of nitric oxide and other vasodilators → splanchnic arterial vasodilatation
2. → fall in effective arterial blood volume despite total body fluid overload
3. → activation of the renin–angiotensin–aldosterone system, sympathetic nervous system and ADH
4. → intense renal vasoconstriction with reduced renal blood flow and glomerular filtration
5. → sodium and water retention, worsening ascites, and progressive renal failure
Additionally, systemic inflammation and bacterial translocation (particularly with SBP) and cirrhotic cardiomyopathy (an inadequate cardiac output response) contribute — which is why infection is the commonest precipitant.
Classification
| Type | Course | Precipitant | Prognosis |
|---|---|---|---|
| HRS–AKI (formerly type 1) | Rapidly progressive — doubling of creatinine within 2 weeks | Often SBP, gastrointestinal bleeding, large-volume paracentesis without albumin, aggressive diuresis | Poor — median survival of weeks without treatment |
| HRS–NAKI (formerly type 2) | Slowly progressive | Usually spontaneous | Associated with refractory ascites; median survival months |
Diagnostic Criteria
1. Cirrhosis with ascites (or acute liver failure)
2. Acute kidney injury by standard criteria
3. No improvement after 2 days of diuretic withdrawal AND volume expansion with intravenous ALBUMIN — this step is both diagnostic and therapeutic, and is what distinguishes HRS from pre-renal azotaemia
4. Absence of shock
5. No current or recent nephrotoxic drugs (NSAIDs, aminoglycosides, contrast)
6. No structural kidney disease — proteinuria < 500 mg/day, no microhaematuria, normal renal ultrasound
Characteristic urinary findings — reflecting intense sodium avidity with intact tubules:
- Urine sodium very low (< 10 mEq/L)
- Fractional excretion of sodium < 1%
- Urine osmolality > plasma osmolality
- Bland urinary sediment — no casts, no significant proteinuria (in contrast to acute tubular necrosis, which shows muddy brown granular casts and a high urine sodium)
Differential Diagnosis of Renal Failure in Cirrhosis
| Cause | Distinguishing features |
|---|---|
| Pre-renal azotaemia | RESPONDS to volume expansion; low urine sodium; history of diuresis, diarrhoea, bleeding |
| Hepatorenal syndrome | Does not respond to volume expansion; very low urine sodium; bland sediment |
| Acute tubular necrosis | High urine sodium (> 40), FENa > 2%, muddy brown granular casts; history of shock, sepsis or nephrotoxins |
| Glomerulonephritis | Proteinuria, haematuria, red cell casts; associated with hepatitis B and C |
| Post-renal obstruction | Dilated system on ultrasound |
Management
1. Prevention — far more effective than treatment
- Albumin infusion with large-volume paracentesis (for taps over about 5 litres).
- Albumin with antibiotics in spontaneous bacterial peritonitis — this specifically reduces the incidence of HRS and improves survival, and is one of the best-evidenced interventions in hepatology.
- Avoid nephrotoxins — NSAIDs, aminoglycosides, contrast; avoid ACE inhibitors and ARBs in advanced cirrhosis.
- Careful diuretic use with monitoring; avoid over-diuresis.
- Antibiotic prophylaxis in high-risk patients (low ascitic protein, previous SBP, gastrointestinal bleeding).
2. General measures on presentation
- Withdraw all diuretics and nephrotoxic drugs.
- Volume expansion with intravenous albumin — both diagnostic and therapeutic.
- Identify and treat precipitants — especially infection; perform a diagnostic ascitic tap and take cultures; treat gastrointestinal bleeding.
- Monitor fluid balance, weight, electrolytes and renal function closely.
3. Specific pharmacological therapy
- TERLIPRESSIN with intravenous ALBUMIN — the treatment of choice. Terlipressin is a splanchnic vasoconstrictor that reverses the splanchnic vasodilatation at the root of the syndrome, restoring effective arterial volume; albumin expands the volume and binds inflammatory mediators. Watch for ischaemic complications (digital, cardiac, mesenteric) and hyponatraemia.
- Alternatives where terlipressin is unavailable: noradrenaline with albumin (requiring intensive care), or midodrine with octreotide and albumin.
4. Renal replacement therapy — as a bridge to transplantation or where there is a reversible precipitant; it does not alter the natural history in the absence of transplantation.
5. TIPS — may improve renal function in selected patients with preserved liver function, but risks encephalopathy.
6. LIVER TRANSPLANTATION — the only definitive treatment. All patients with HRS should be assessed urgently for transplantation, since HRS reflects end-stage liver disease and carries a very poor prognosis without it. Combined liver–kidney transplantation is considered where renal failure has been prolonged.
Hepatorenal syndrome is a diagnosis of exclusion, and the commonest error is to make it too quickly. Before accepting it, you must stop the diuretics, give a proper albumin volume challenge, look actively for infection with a diagnostic ascitic tap, review every drug for nephrotoxicity, and examine the urinary sediment. Many patients labelled with HRS in fact have reversible pre-renal failure or acute tubular necrosis, which have entirely different treatments and much better outcomes — and the label itself risks a nihilistic approach to a treatable problem.
All questions in Hepatology / GIT
- Q1Discuss the aetiology, serology, clinical features, complications and management of viral hepatitis. ★
- Q2Discuss the aetiology, clinical features, complications, investigations and management of cirrhosis of the liver. ★
- Q3Discuss the causes, clinical assessment and management of upper gastrointestinal bleeding. ★
- Q4Discuss the aetiology, clinical features, severity assessment, complications and management of acute pancreatitis. ★
- SN1Write a short note on the approach to jaundice and interpretation of liver function tests.
- SN2Write a short note on acute liver failure.
- SN3Write a short note on non-alcoholic fatty liver disease and alcoholic liver disease.
- SN4Write a short note on portal hypertension and ascites.
- SN5Write a short note on hepatic encephalopathy.
- SN6Write a short note on hepatorenal syndrome.
- SN7Write a short note on spontaneous bacterial peritonitis and secondary peritonitis.
- SN8Write a short note on amoebiasis — intestinal and hepatic.
- SN9Write a short note on Wilson's disease.
- SN10Write a short note on the clinical approach to hepatomegaly and splenomegaly.
- SN11Write a short note on peptic ulcer disease, Helicobacter pylori and Zollinger-Ellison syndrome.
- SN12Write a short note on gastro-oesophageal reflux disease.
- SN13Write a short note on chronic diarrhoea and malabsorption.
- SN14Write a short note on inflammatory bowel disease.
- SN15Write a short note on acute infective diarrhoea — cholera and bacillary dysentery.
- SN16Write a short note on lower gastrointestinal bleeding.